News

Irvine Clinical Research Announces Success of Alzheimer's Study

 Last week, Eisai and Biogen announced successful results in its Phase 3 clinical trial of the drug lecanamab. The drug delayed progression of cognitive loss in a double-blind, placebo-controlled, randomized drug trial by 27%.

The study was based on 1,795 patients, 25 percent of whom in the US were Hispanic and African American. Participants received either the drug or a placebo every two weeks for eighteen months. Cognitive decline was measured using a scale that factored: memory, orientation, judgement, problem solving, community affairs, home, hobbies, and personal care.

The study is the largest yet conducted to target cleaning amyloid plaque buildup in the brain to treat and slow cognitive decline. The drug was also judged to be safer than others in its class, with less than 3% of patients experiencing symptoms related to brain imaging abnormalities (more patients experienced this side effect without symptoms). With this promising data, we expect the FDA to clear the drug for public use soon, adding a powerful new tool to the arsenal for treating Alzheimer's disease and cognitive decline.

Irvine Clinical Research was one of the sites in the trial, and we are proud to have been a part of this landmark study. We are certain this will open new pathways for future research, and we look forward to working with our staff, patients, and drug sponsors towards a cure for Alzheimer's.

If you would like to participate in one of our clinical studies, please Contact Us.